Document is current
Any future updates will be listed below
-
Authors
Castagnetti, Fausto https://orcid.org/0000-0002-0602-2628
Breccia, Massimo https://orcid.org/0000-0003-1163-6162
Abruzzese, Elisabetta https://orcid.org/0000-0001-5228-6491
Bassan, Renato https://orcid.org/0000-0001-8214-2894
Binotto, Gianni
Bonifacio, Massimiliano https://orcid.org/0000-0003-0716-1686
Caocci, Giovanni https://orcid.org/0000-0002-6585-5187
Capodanno, Isabella
Cavazzini, Francesco
Cimino, Giuseppe
Fazi, Paola
Gozzini, Antonella
Iurlo, Alessandra https://orcid.org/0000-0002-4401-0812
Janssen, Jeroen J. W. M.
Lunghi, Monia
Marasca, Roberto https://orcid.org/0000-0002-6431-6878
Martino, Bruno
Messina, Monica
Muriano, Francesco https://orcid.org/0009-0001-4737-4451
Paoloni, Francesca
Piciocchi, Alfonso
Rosti, Gianantonio
Russo Rossi, Antonella
Saglio, Giuseppe https://orcid.org/0000-0002-1046-3514
Sica, Simona https://orcid.org/0000-0003-2426-3465
Soverini, Simona
Tafuri, Agostino
Vallisa, Daniele
Westerweel, Peter E. https://orcid.org/0000-0002-0746-7039
Pane, Fabrizio
- License Information
-
More Information
Article History
Received: 4 March 2025
Revised: 30 July 2025
Accepted: 27 October 2025
First Online: 18 November 2025
Competing interests
: FC: Pfizer : Consultancy, Honoraria, Research Funding; BMS : Honoraria; Incyte : Consultancy, Honoraria; Novartis : Consultancy, Honoraria, Research Funding. MB: AOP , Pfizer, BMS, Incyte , AbbVie , Novartis : Honoraria. EA: BMS : Consultancy, Membership on an entity’s Board of Directors or advisory committees; Incyte : Consultancy, Membership on an entity’s Board of Directors or advisory committees; Novartis : Consultancy, Membership on an entity’s Board of Directors or advisory committees; Pfizer : Consultancy; Takeda : Consultancy. GB: Novartis , AOP, BMS , Incyte , GSK : Honoraria. MB: Amgen, Ascentage Pharma, Blueprint Medicines, BMS, GSK, Incyte, Novartis , Pfizer: Honoraria/Adv board. F.C.: Novartis : Honoraria; Incyte : Honoraria; Pfizer : Honoraria. AI: AOP, Pfizer, BMS, Incyte , Abb Vie, Novartis, GSK: Honoraria. JJWMJ: Novartis : Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; BMS : Other, Research Funding; Amgen : Other; Astellas : Other; Daiichi-Sankyo : Other; Janssen : Other; Olympus : Other; Incyte : Honoraria, Membership on an entity’s Board of Directors or advisory committees, Other; Sanofi Gemzyme : Other; Servier : Other; Jazz : Other; Takeda : Other; Abbvie : Honoraria, Membership on an entity’s Board of Directors or advisory committees; Pfizer : Honoraria, Membership on an entity’s Board of Directors or advisory committees. RM: Abbvie, Janssen, Astra Zeneca : Membership on an entity’s Board of Directors or advisory committees, Research Funding, Speakers Bureau. GR: Novartis , Incyte, Pfizer : Other, Speakers Bureau. SSo: Incyte, Novartis : Consultancy, Honoraria. PEW: Pfizer , Novartis , Incyte, Bristol Myers Squibb- Celgene : Honoraria. FP: Incyte : Honoraria, Speakers Bureau; BMS : Speakers Bureau; Novartis : Honoraria, Speakers Bureau; Pfizer : Speakers Bureau. The authors declare no competing interests.
: The study ( NCT02602314) was approved by Ethics Committee “Università Federico II”, with the reference number 121_13_ES5. The study is being conducted in accordance with the Declaration of Helsinki and the International Councilfor Harmonisation Harmonized Tripartite Guidelines for GCP. The participants provided their written informed consent to participate in this study.
